Device Trial Radar · NCT06305663
A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children
Last checked: Nov 20, 2026Latest source record: Jun 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
418
Planned (sponsor's estimate)
Start
Mar 29, 2024
Primary completion
Jan 31, 2027
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 12, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 8 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children
Conditions
- Myopia
Interventions
Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)Device
Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)
CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact LensDevice
CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in axial length.Time frame: 1 and 2 years
- Mean change from baseline in cycloplegic SERE.Time frame: 1 and 2 years
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Site 105
Beijing, Beijing Municipality, China · Active not recruiting
Site 107
Dongcheng, Beijing Municipality, China · Active not recruiting
Site 109
Xiamen, Fujian, China · Active not recruiting
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.